{"id":"W4401364054","doi":"10.1093/oncolo/oyae181.026","title":"8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Nivolumab; Ipilimumab; Sunitinib; Renal cell carcinoma; Medicine; Internal medicine; Oncology; Phases of clinical research; Clinical trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003153036,0.0003974309,0.000895289,0.000110963,0.0002069251,0.00004263851,0.0002416972,0.0001181318,0.00008765698],"category_scores_gemma":[0.0001376572,0.0001873906,0.0003620802,0.0004173883,0.0002795547,0.00007504169,0.00005367382,0.0002159054,0.00001980174],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001192109,"about_ca_system_score_gemma":0.0005469237,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004927036,"about_ca_topic_score_gemma":0.003579724,"domain_scores_codex":[0.9977667,0.0002346501,0.0006359862,0.000530808,0.0003933032,0.0004385779],"domain_scores_gemma":[0.997358,0.001309788,0.0003193891,0.0007492171,0.0001540075,0.0001096027],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9077002,0.01211857,0.0220253,0.0004088779,0.001846586,0.0006227963,0.008845437,0.003826785,0.003136471,0.00005844851,0.002369104,0.0370414],"study_design_scores_gemma":[0.7805327,0.1141077,0.02242448,0.0003920066,0.00602233,0.00001254845,0.00307888,0.004364056,0.05855854,0.000293791,0.009650176,0.0005628513],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909256,0.002124683,0.00007939475,0.0005079156,0.000364611,0.004034341,0.000855329,0.00005980476,0.001048364],"genre_scores_gemma":[0.9958258,0.000313742,0.0004993727,0.00003788002,0.0002910149,0.0007081899,0.0006637903,0.00005691838,0.001603248],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1271676,"threshold_uncertainty_score":0.7641568,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07148638069975227,"score_gpt":0.3484030131394102,"score_spread":0.2769166324396579,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}